Use of rituximab and plasma exchange in treatment and prophylaxis of recurrent FSGS
We conclude that rituximab did not add significant benefit to plasma exchange when used as initial therapeutic intervention in post-transplant recurrent FSGS. The modest benefit of prophylactic therapies highlights the need for risk stratification to identify patients most likely to benefit from such interventions. Larger prospective studies with standardized approaches to treatment are essential in improving outcomes in rFSGS.
Authors
- Sophie Gharaei (ORCID: https://orcid.org/0000-0002-1122-1293)
- Durga Kanigicherla (ORCID: https://orcid.org/0000-0003-3011-7878)
- Omar Ragy (ORCID: https://orcid.org/0000-0003-0958-2783)
- J Mahmoudi Gharaei
Institutions
- Manchester Academic Health Science Centre (GB)
- University of Manchester (GB)
- Manchester VA Medical Center (US)
- Universidad Europea (MX)
- NIHR Manchester Biomedical Research Centre (GB)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1093/ckj/sfaf058
- Citations
- 1
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.47